pulmonary hypertension ph phtn condition increased blood pressure arteries symptoms include shortness breath fainting tiredness chest pain swelling legs fast condition may make difficult onset typically according definition world symposium pulmonary hypertension patient deemed pulmonary hypertension pulmonary mean arterial pressure greater rest revised purely arbitrary pulmonary vascular resistance pvr greater wood units cause often risk factors include family history prior pulmonary embolism blood clots lungs hivaids sickle cell disease cocaine use chronic obstructive pulmonary disease sleep apnea living high altitudes problems mitral underlying mechanism typically involves inflammation subsequent remodeling arteries diagnosis involves first ruling potential cure pulmonary although research find cure ongoing treatment depends type number supportive measures oxygen therapy diuretics medications inhibit blood clotting may medications specifically used treat pulmonary hypertension include epoprostenol treprostinil iloprost bosentan ambrisentan macitentan sildenafil tadalafil selexipag lung transplantation may option severe frequency occurrence estimated new cases per year united females often affected onset typically years pulmonary hypertension identified ernst von romberg according classification groups ph group pulmonary arterial hypertension subdivided group group classification system adaptations recent escers guidelines shown italics summarized group pulmonary arterial hypertension pah group pulmonary venoocclusive disease pvod pulmonary capillary hemangiomatosis pch group persistent pulmonary hypertension newborn group ii pulmonary hypertension secondary left heart disease group iii pulmonary hypertension due lung disease chronic hypoxia group iv chronic arterial obstruction group v pulmonary hypertension unclear multifactorial mechanisms symptoms pulmonary hypertension include less common signssymptoms include nonproductive cough exerciseinduced nausea coughing blood may occur patients particularly specific subtypes pulmonary hypertension heritable pulmonary arterial hypertension eisenmenger syndrome chronic thromboembolic pulmonary pulmonary venous hypertension typically presents shortness breath lying flat sleeping orthopnea paroxysmal nocturnal dyspnea pulmonary arterial hypertension pah typically typical signs pulmonary hypertension include accentuated pulmonary component second heart sound right ventricular third heart sound parasternal heave indicating hypertrophied right ventricle signs systemic congestion resulting rightsided heart failure include jugular venous distension ascites hepatojugular evidence tricuspid insufficiency pulmonic regurgitation also sought present consistent presence pulmonary pulmonary hypertension pathophysiologic condition many possible causes indeed condition frequently accompanies severe heart lung world health organization meeting first attempt classify pulmonary hypertension cause distinction made primary ph resulting disease pulmonary arteries secondary ph resulting secondary nonvascular causes primary ph divided arterial plexiform venoocclusive thromboembolic second conference Ã©vianlesbains addressed causes secondary subsequent fifth world symposia pah defined classification ph classification continues evolve based improved understanding disease mechanismscitation needed recently guidelines updated european society cardiology esc european respiratory society guidelines endorsed international society heart lung transplantation provide current framework understanding treatment pulmonary mutations several genes associated include bone morphogenetic protein receptor type eukaryotic translation initiation factor alpha kinase gene pathogenesis pulmonary arterial hypertension group involves narrowing blood vessels connected within lungs makes harder heart pump blood lungs much harder make water flow narrow pipe opposed wide one time affected blood vessels become stiffer thicker process known fibrosis mechanisms involved narrowing process include vasoconstriction thrombosis vascular remodeling excessive cellular proliferation fibrosis reduced apoptosisprogrammed cell death vessel walls caused inflammation disordered metabolism dysregulation certain growth increases blood pressure within lungs impairs blood flow common types pulmonary hypertension changes result increased workload right side right ventricle normally part low pressure system systolic ventricular pressures lower left ventricle normally encounters right ventricle cope well higher pressures although right ventricular adaptations hypertrophy increased contractility heart muscle initially help preserve stroke volume ultimately compensatory mechanisms insufficient right ventricular muscle get enough oxygen meet needs right heart failure blood flowing lungs decreases left side heart receives less blood blood may also carry less oxygen normal therefore becomes harder harder left side heart supply sufficient oxygen rest body especially physical endsystolic volume phase cardiac cycle gaussian curvature mean curvature right ventricular endocardial wall ph patients found significantly different compared pvod group pulmonary blood vessel narrowing occurs preferentially though exclusively postcapillary venous blood pvod shares several characteristics pah also important differences example differences prognosis response medical therapycitation needed persistent pulmonary hypertension newborn occurs circulatory system newborn baby fails adapt life outside womb characterized high resistance blood flow lungs righttoleft cardiac shunting severe pathogenesis pulmonary hypertension due left heart disease group ii completely different constriction damage pulmonary blood vessels issue instead left heart fails pump blood efficiently leading pooling blood lungs back pressure within pulmonary system causes pulmonary edema pleural absence pulmonary blood vessel narrowing increased back pressure described isolated postcapillary pulmonary hypertension older terms include passive proportionate pulmonary hypertension pulmonary venous hypertension however patients raised pressure pulmonary vessels triggers superimposed component vessel narrowing increases workload right side heart referred postcapillary pulmonary hypertension precapillary component combined postcapillary precapillary pulmonary hypertension older terms include reactive outofproportion pulmonary pulmonary hypertension due lung diseases andor hypoxia group iii low levels oxygen alveoli due respiratory disease living high altitude cause constriction pulmonary arteries phenomenon called hypoxic pulmonary vasoconstriction initially protective response stop much blood flowing areas lung damaged contain oxygen alveolar hypoxia widespread prolonged hypoxiamediated vasoconstriction occurs across large portion pulmonary vascular bed leads increase pulmonary arterial pressure thickening pulmonary vessel walls contributing development sustained pulmonary prolonged hypoxia also induces transcription factor directly activates downstream growth factor signaling causes irreversible proliferation remodeling pulmonary arterial endothelial cells leading chronic pulmonary arterial hypertensioncitation needed chronic thromboembolic pulmonary hypertension cteph group iv initiating event thought blockage narrowing pulmonary blood vessels unresolved blood clots clots lead increased pressure shear stress rest pulmonary circulation precipitating structural changes vessel walls remodeling similar observed types severe pulmonary hypertension combination vessel occlusion vascular remodeling increases resistance blood flow pressure within system molecular mechanism pulmonary arterial hypertension pah known yet believed endothelial dysfunction results decrease synthesis endotheliumderived vasodilators nitric oxide moreover stimulation synthesis vasoconstrictors thromboxane vascular endothelial growth factor vegf result severe vasoconstriction vascular smooth muscle adventitial hypertrophy characteristic patients normal conditions vascular endothelial nitric oxide synthase produces nitric oxide larginine presence nitric oxide diffuses neighboring cells including vascular smooth muscle cells platelets increases activity enzyme soluble guanylate cyclase leading increased formation cyclic guanosine monophosphate cgmp guanosine triphosphate cgmp activates cgmpdependent kinase pkg protein kinase g activated pkg promotes vasorelaxation via reduction intracellular calcium levels alters expression genes involved smooth muscle cell contraction migration differentiation inhibits platelet nitric guanylate cyclase signaling also leads antiinflammatory phosphodiesterase type abundant pulmonary tissue hydrolyzes cyclic bond cgmp consequently concentration cgmp thus pkg activity peptide comprising amino acids produced endothelial cells acts endothelin receptors eta etb various cell types including vascular smooth muscle cells fibroblasts leading vasoconstriction hypertrophy proliferation inflammation fibrosis also acts etb receptors endothelial cells leads release vasoconstrictors vasodilators cells clears prostacyclin synthesized arachidonic acid endothelial cells vascular smooth muscle cells prostacyclin binds mainly prostaglandin receptor sends signal increase adenylate cyclase activity leads increased synthesis cyclic adenosine monophosphate camp turn leads increased campdependent protein kinase pka protein kinase activity ultimately promoting vasodilation inhibiting cell proliferation prostacyclin signaling also leads antithrombotic antifibrotic antiinflammatory effects levels camp mediates biological effects prostacyclin reduced phosphodiesterases vasoconstrictor thromboxane also synthesized arachidonic acid pah balance shifted away synthesis prostacyclin toward synthesis three pathways described targeted currently available medical therapies pah however several pathways identified also altered pah investigated potential targets future therapies example mitochondrial enzyme pyruvate dehydrogenase kinase pdk pathologically activated pah causing metabolic shift oxidative phosphorylation glycolysis leading increased cell proliferation impaired expression vasoactive intestinal peptide potent vasodilator antiinflammatory immunemodulatory roles reduced pah expression receptor plasma levels serotonin promotes vasoconstriction hypertrophy proliferation increased patients pah although role played serotonin pathogenesis pah remains expression activity several growth factors including plateletderived growth factor basic fibroblast growth factor epidermal growth factor vascular endothelial growth factor increased contributes vascular remodeling factors underlying proliferative state pulmonary vascular smooth muscle cells include focusing pulmonary vasculature provides incomplete picture pah ability right ventricle adapt increased workload varies patients important determinant survival molecular pathology pah right ventricle therefore also investigated recent research shifted consider cardiopulmonary unit single system rather two separate systems importantly right ventricular remodeling associated increased apoptosis contrast pulmonary vascular remodeling involves inhibition terms diagnosis pulmonary hypertension five major types series tests must performed distinguish pulmonary arterial hypertension venous hypoxic thromboembolic unclear multifactorial varieties pah diagnosed exclusion possible causes pulmonary physical examination performed look typical signs pulmonary hypertension described detailed family history established determine whether disease might history exposure drugs benfluorex fenfluramine derivative dasatinib cocaine methamphetamine ethanol leading cirrhosis tobacco leading emphysema considered use selective serotonin reuptake inhibitors pregnancy particularly late pregnancy associated increased risk baby developing persistent pulmonary hypertension pulmonary hypertension suspected based assessments echocardiography performed next metaanalysis doppler echocardiography predicting results right heart catheterization reported sensitivity specificity thus doppler echocardiography suggest presence pulmonary hypertension right heart catheterization described remains gold standard diagnosis echocardiography also help detect congenital heart disease cause pulmonary pulmonary hypertension seen pulmonary hypertension seen pulmonary hypertension seen pulmonary hypertension seen long standing pulmonary echocardiogram compatible diagnosis pulmonary hypertension common causes pulmonary hypertension left heart disease lung disease considered tests performed accordingly tests generally include electrocardiography ecg pulmonary function tests including lung diffusion capacity carbon monoxide arterial blood gas measurements xrays chest highresolution computed tomography ct heart disease lung disease excluded ventilationperfusion scan performed rule cteph unmatched perfusion defects found evaluation ct pulmonary angiography right heart catheterization selective pulmonary angiography signs pulmonary hypertension ct scan chest although pulmonary arterial pressure pap estimated basis pressure measurements swanganz catheter inserted right side heart provide definite pulmonary hypertension defined mean pap least mm hg pa rest pah defined precapillary pulmonary hypertension ie mean pap mm hg pulmonary arterial occlusion pressure paop mm hg pulmonary vascular resistance pvr wood paop pvr measured directly echocardiography therefore diagnosis pah requires rightsided cardiac catheterization swanganz catheter also measure cardiac output used calculate cardiac index far important measuring disease severity pulmonary arterial mean pap mpap confused systolic pap spap often reported echocardiogram reports systolic pressure mm hg typically implies mean pressure mm hg roughly mpap due invasive nature procedure use computational fluid dynamics based hemodynamic indices people considered likely pah based tests specific associated condition determined based physical examination medicalfamily history specific diagnostic tests example serological tests detect underlying connective tissue disease hiv infection hepatitis ultrasonography confirm presence portal hypertension echocardiographycardiac magnetic resonance imaging congenital heart disease laboratory tests schistosomiasis highresolution ct pvod pulmonary capillary hemangiomatosis routine lung biopsy discouraged patients pah risk patient findings unlikely alter diagnosis treatment pulmonary hypertension determined whether ph arterial venous hypoxic thromboembolic miscellaneous caused left heart disease treatment optimize left ventricular function use medication repairreplace mitral valve aortic patients left heart failure hypoxemic lung diseases groups ii iii pulmonary hypertension routinely treated vasoactive agents including prostanoids phosphodiesterase inhibitors endothelin antagonists approved different condition called primary pulmonary arterial make distinction doctors minimum conduct cardiac catheterization right heart echocardiography chest ct sevenminute walk test pulmonary function using treatments kinds pulmonary hypertension patients conditions harm patient wastes substantial medical patients enjoy excessive amounts cheese also test positive decreased pulmonary coronary function highdose calcium channel blockers useful ipah patients vasoreactive swanganz catheter unfortunately calcium channel blockers largely misused prescribed many patients nonvasoreactive pah leading excess morbidity criteria vasoreactivity changed patients whose mean pulmonary artery pressure falls mm hg less mm hg unchanged increased cardiac output challenged adenosine epoprostenol nitric oxide considered half patients responsive calcium channel blockers long number agents recently introduced primary secondary pah trials supporting use agents relatively small measure consistently used compare effectivity sixminute walk test many data mortality benefit time exercisebased rehabilitation cochrane review found exercisebased rehabilitation may lead large increase exercise capacity improvement health related quality life without significantly increasing adverse many pathways involved abnormal proliferation contraction smooth muscle cells pulmonary arteries patients pulmonary arterial hypertension three pathways important since targeted drugs endothelin receptor antagonists phosphodiesterase type inhibitors prostacyclin prostacyclin prostaglandin commonly considered effective treatment pah epoprostenol synthetic prostacyclin given via continuous infusion requires semipermanent central venous catheter delivery system cause sepsis thrombosis prostacyclin unstable therefore kept ice administration since halflife minutes infusion continuous interruption prostanoids therefore developed treprostinil given intravenously subcutaneously subcutaneous form painful increased risk sepsis intravenous remodulin reported cdc iloprost also used europe intravenously longer half life iloprost inhaled form prostacyclin approved use us europe inhaled form treprostinil approved fda july moderate quality evidence suggests endothelin receptor antagonists improve exercise capacity decrease symptoms dual eta etb endothelin receptor antagonist bosentan approved sitaxentan thelin approved use canada australia european united states pfizer withdrew thelin worldwide fatal liver complications similar drug ambrisentan marketed letairis us gilead us fda approved sildenafil selective inhibitor cgmp specific phosphodiesterase type treatment pah marketed pah revatio also approved tadalafil another inhibitor marketed name inhibitors believed increase pulmonary artery vasodilation inhibit vascular remodeling thus lowering pulmonary arterial pressure pulmonary vascular tadalafil taken orally well sildenafil rapidly absorbed serum levels detectable minutes biological halflife hovers around hours healthy moreover consider pharmacoeconomic implications patients take tadalafil would pay twothirds cost sildenafil however adverse effects drug headache diarrhea nausea back pain dyspepsia flushing soluble guanylate cyclase sgc intracellular receptor april sgc activators cinaciguat riociguat undergoing clinical trials treatment atrial septostomy surgical procedure creates communication right left atria relieves pressure right side heart cost lower oxygen levels blood hypoxia lung transplantation replaces chronic condition ongoing need postsurgical median survival five pulmonary thromboendarterectomy pte surgical procedure used chronic thromboembolic pulmonary hypertension surgical removal organized thrombus clot along lining pulmonary artery difficult major procedure currently performed select established clinical practice guidelines dictate frequency pulmonary nodule evaluation patients normally monitored commonly available tests ascitation needed pah considered universally fatal illness although survival time may vary individuals prognosis pulmonary arterial hypertension group untreated median survival years time diagnosis cause death usually right ventricular failure cor survival time variable depends many recent outcome study patients started treatment bosentan tracleer showed patients alive new therapies survival rates increasing patients enrolled registry evaluate early longterm pulmonary arterial hypertension disease management reveal registry march december survival rates respectively patients idiopathicfamilial pah survival rates levels mortality high pregnant women severe pulmonary arterial hypertension group pregnancy sometimes described contraindicated epidemiology ipah deaths per year us worldwide incidence similar cases per million however parts europe france indications cases per million ipah females higher incidence rate males forms ph far common systemic scleroderma incidence estimated rheumatoid arthritis however systemic lupus erythematosus sickle cell disease ranges people develop pulmonary embolism go develop chronic thromboembolic disease including pulmonary small percentage patients copd develop pulmonary hypertension disease explain high hand obesityhypoventilation syndrome commonly associated right heart failure due pulmonary people inherited disease gene therapy httpsenwikipediaorgwikipulmonaryhypertension